2024
Cathepsin B Nuclear Flux in a DNA-Guided “Antinuclear Missile” Cancer Therapy
Cao F, Tang C, Chen X, Tu Z, Jin Y, Turk O, Nishimura R, Ebens A, Dubljevic V, Campbell J, Zhou J, Hansen J. Cathepsin B Nuclear Flux in a DNA-Guided “Antinuclear Missile” Cancer Therapy. ACS Central Science 2024, 10: 1562-1572. PMID: 39220699, PMCID: PMC11363321, DOI: 10.1021/acscentsci.4c00559.Peer-Reviewed Original ResearchAntinuclear antibodiesCancer therapyTumor-specific surface antigenLysosomal protease cathepsin BAntibody-drug conjugatesNecrotic tumorTumor environmentExtracellular nucleic acidsSurface antigensProtease cathepsin BCancer cellsTumorNucleoside salvage pathwayDrug linkersNucleoside salvageTherapyCross membrane barriersMembrane barrierCathepsin BLiving cancer cellsDNA guidesAntinuclearSalvage pathwayCathepsinNuclear penetrationNuclear-penetrating scleroderma autoantibody inhibits topoisomerase 1 cleavage complex formation
May C, Noble P, Herzog E, Meffre E, Hansen J. Nuclear-penetrating scleroderma autoantibody inhibits topoisomerase 1 cleavage complex formation. Biochemical And Biophysical Research Communications 2024, 720: 150123. PMID: 38759301, DOI: 10.1016/j.bbrc.2024.150123.Peer-Reviewed Original ResearchDiffuse cutaneous systemic sclerosisCutaneous systemic sclerosisAnti-topoisomerase 1Systemic lupus erythematosusDiscovery of autoantibodiesMechanisms of autoimmunityInhibit DNA repairScleroderma autoantibodiesScleroderma subtypeSystemic sclerosisLupus erythematosusAutoantibodiesCancer therapyPathophysiologyReagent resourcesCellular dysfunctionAntibodiesCell nucleiDNA repair
2015
Optimizing a Lupus Autoantibody for Targeted Cancer Therapy
Noble PW, Chan G, Young MR, Weisbart RH, Hansen JE. Optimizing a Lupus Autoantibody for Targeted Cancer Therapy. Cancer Research 2015, 75: 2285-2291. PMID: 25832653, DOI: 10.1158/0008-5472.can-14-2278.Peer-Reviewed Original Research
2012
Targeting Cancer with a Lupus Autoantibody
Hansen JE, Chan G, Liu Y, Hegan DC, Dalal S, Dray E, Kwon Y, Xu Y, Xu X, Peterson-Roth E, Geiger E, Liu Y, Gera J, Sweasy JB, Sung P, Rockwell S, Nishimura RN, Weisbart RH, Glazer PM. Targeting Cancer with a Lupus Autoantibody. Science Translational Medicine 2012, 4: 157ra142. PMID: 23100628, PMCID: PMC3713477, DOI: 10.1126/scitranslmed.3004385.Peer-Reviewed Original ResearchConceptsSystemic lupus erythematosusAnti-DNA antibodiesLupus autoantibodiesProstate cancerCancer therapyLupus anti-DNA antibodiesHuman tumor xenograftsDNA-damaging therapiesCultured tumor cellsSLE patientsLupus erythematosusSLE pathophysiologyAutoimmune diseasesDose doxorubicinTumor xenograftsAutoantibodiesHuman cancer cellsTherapyTherapeutic agentsTumor cellsCancerCancer cellsLupusMalignancyPrecise roleA Cell-Penetrating Bispecific Antibody for Therapeutic Regulation of Intracellular Targets
Weisbart RH, Gera JF, Chan G, Hansen JE, Li E, Cloninger C, Levine AJ, Nishimura RN. A Cell-Penetrating Bispecific Antibody for Therapeutic Regulation of Intracellular Targets. Molecular Cancer Therapeutics 2012, 11: 2169-2173. PMID: 22863609, DOI: 10.1158/1535-7163.mct-12-0476-t.Peer-Reviewed Original ResearchConceptsBispecific antibodiesBispecific single-chain Fv fragmentsMonoclonal antibody 3G5Cancer therapyDelivery of antibodiesIntracellular targetsMolecular therapyTherapeutic useTherapeutic regulationMonoclonal antibodiesTherapyAntibodiesMAb 3E10Single-chain Fv fragmentInhibits growthP53 levelsImportant targetMDM2Limited accessFv fragmentTargetTumors